



(51) International Patent Classification:

C07D 471/08 (2006.01) A61P 31/12 (2006.01)

A61K 31/4178 (2006.01)

(21) International Application Number:

PCT/US2013/044138

(22) International Filing Date:

4 June 2013 (04.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/655,934 5 June 2012 (05.06.2012) US

61/759,295 31 January 2013 (31.01.2013) US

13/800,374 13 March 2013 (13.03.2013) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333

Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: SCOTT, Robert William; c/o Gilead Sciences,

Inc., 333 Lakeside Drive, Foster City, California 94404

(US). WANG, Fang; c/o Gilead Sciences, Inc., 333

Lakeside Drive, Foster City, California 94404 (US). SHI,

Bing; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster

City, California 94404 (US). MOGALIAN, Erik; c/o

Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,

California 94404 (US).

(74) Agents: TANNER, Lorna L. et al.; Sheppard Mullin

Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto,

California 94301-1479 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))


— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: SOLID FORMS OF AN ANTIVIRAL COMPOUND



Compound I

(57) Abstract: Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl]-9H-fluoren-2-yl)-1H-benzimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: (Compound (I)). Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.